Luye Pharma’s LY03005 Approved by China’s CDE to Conduct Phase III Clinical Trial for th...

Luye Pharma Files New Drug Application for Lurbinectedin in Hong Kong

For the Treatment of Metastatic Small Cell Lung Cancer

Luye Pharma and Biostar Enter into a Partnership for Marketing Innovative Anticancer Drug ...

Marketing Authorization Application for Luye Pharma's Innovative Anticancer Formulation Go...

Luye Pharma Releases Top-Line Results from a Phase II Clinical Trial of Its New Antidepres...

Showing a comprehensive antidepressant efficacy and a good safety profile

Luye Pharma Grants Gensci Exclusive Commercialization Rights of Rivastigmine Transdermal P...